Loading provider…
Loading provider…
Internal Medicine Physician in Washington, DC
NPI: 1194834754Primary Practice Location
Howard University
2139 Georgia NW Ave, Washington, DC
Primary Employer
Faculty Practice Plan Howard University
hufpp.com
HQ Phone
Get MD Siham's Phone Numberphone_androidMobile
Get MD Siham's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
VA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 11 | 18 |
Authors: Anne Luetkemeyer, Ann Falsey, Richard Novak, Patricia Winokur, Dahlene Fusco, Angelica Kottkamp, John Beigel, Richard Rupp, Robert Atmar, David Diemert, Rachel Presti, Jennifer Whitaker, Nadine Rouphael, Susan Little, Lindsey Baden, Emmanuel Walter, Paul Goepfert
Journal: J Infect Dis
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.
Authors: Laura Porterfield, Anne Luetkemeyer, Ann Falsey, Richard Novak, Patricia Winokur, Dahlene Fusco, Angelica Kottkamp, Edward Walsh, Thomas Martin, John Beigel, Richard Rupp, Stephen Walsh, Benjamin Ladner, Anna Wald, Michael Smith, Robert Atmar, David Diemert, Rachel Presti, Jennifer Whitaker, Christina Rostad
Authors: Anne Luetkemeyer, Ann Falsey, Richard Novak, Patricia Winokur, Dahlene Fusco, Angelica Kottkamp, John Beigel, Richard Rupp, Robert Atmar, David Diemert, Rachel Presti, Jennifer Whitaker, Lindsey Baden, Emmanuel Walter, Paul Goepfert
Journal: medRxiv
Publication Date: 2023-03-31
Lead Sponsor: Novavax
Collaborators: Department of Health and Human Services
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination), OTHER: Placebo (Crossover Vaccination period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), OTHER: Placebo (Initial Vaccination Period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
Journal: medRxiv
Publication Date: 2022-07-15